Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Healthcare Spending Totals 42.2 Trillion Yen in FY2020, Showing Record Drop of 1.4 Trillion Yen: MHLW
September 2, 2021
- LDP’s COVID-19 Headquarters Calls for Guidelines on Oral Steroid Administration to Patients Recuperating at Home
September 1, 2021
- Council to Discuss Resuming Active Recommendation of HPV Vaccines: Health Minister
September 1, 2021
- Japan’s Volume-Based Generic Share Reaches 82.1% at End of FY2020, 6 Prefectures Stalling Below 80%: MHLW
September 1, 2021
- MHLW Group Launches Study for Post-Marketing Safety Measures to Boost Global Harmonization, Efficiency
September 1, 2021
- MHLW Panel Shelves Decision on Entresto’s Hypertension Use, Clears Otsuka’s Eczema Med and More
August 31, 2021
- Govt Recognizes Need to Resume HPV Vaccine Discussion: Health Minister
August 31, 2021
- MHLW, Indonesian FDA Ink MOU to Cooperate in Drug Regulations
August 31, 2021
- MHLW to Discuss Ways to Strengthen Stable Supply System of Drugs and Medical Devices: Vice Health Minister
August 30, 2021
- MHLW Discussing Mandatory Reporting System for Unstable Drug Supplies
August 30, 2021
- 500,000 of Suspended Moderna Vaccine Doses Already Used: Kono
August 30, 2021
- Govt Not Planning to Resume Active HPV Vaccine Recommendation before October: Minister
August 30, 2021
- MHLW Health Policy Bureau Seeks FY2022 Budget to Set Up Manufacturing Regime for Stable Supplies
August 27, 2021
- MHLW Health Service Bureau Seeks 468.6 Billion Yen in FY2022, 46% Rise for Infectious Disease Measures
August 27, 2021
- Reinstate Active HPV Vaccine Promotion before October: LDP League
August 27, 2021
- MHLW to Request a Record 34 Trillion Yen General Account Budget for FY2022
August 27, 2021
- MHLW Pharma Safety Bureau Seeks 246 Million Yen to Shake Off Public Distrust in Generics: FY2022 Budget Request
August 27, 2021
- MHLW Won’t Recall Moderna Vaccine Vials for Now
August 26, 2021
- Japan Approves Forxiga for CKD, Rinvoq’s Atopic Dermatitis Use and More
August 26, 2021
- Trade Groups Urges New Reimbursement Fee Evaluation for SaMD
August 26, 2021
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…